ea0029s28.3 | Osteoporosis treatment in 2012 and beyond | ICEECE2012
Ebeling P.
Current osteoporosis therapy is predominantly anti-resorptive. Oestrogen antagonises the action of RANK-Ligand, a potent cytokine for osteoclast differentiation. Amino-bisphosphonates inhibit the HMG CoA reductase pathway, reducing osteoclast activity and viability, while denosumab is a human monoclonal antibody that binds to RANKL. Denosumab treatment reduces fractures. In a study of 7868 women with postmenopausal osteoporosis, denosumab reduced new radiographic v...